Glaucoma-Pipeline Review, H1 2017

Glaucoma-Pipeline Review, H1 2017


  • Products Id :- GMDHC9212IDB
  • |
  • Pages: 280
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Glaucoma-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glaucoma-Pipeline Review, H1 2017, provides an overview of the Glaucoma (Ophthalmology) pipeline landscape.

Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow of the optic nerve. The most important risk factors include age, elevated eye pressure, African ancestry, thin cornea, family history of glaucoma. Signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance, often in low light, blurred vision and reddening of the eye.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glaucoma-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Glaucoma (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glaucoma (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Glaucoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 10, 22, 8, 56, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 10 and 5 molecules, respectively.

Glaucoma (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Glaucoma (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Glaucoma (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Glaucoma (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Glaucoma (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Glaucoma (Ophthalmology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Glaucoma (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Glaucoma (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 6

Glaucoma-Overview 7

Glaucoma-Therapeutics Development 8

Glaucoma-Therapeutics Assessment 23

Glaucoma-Companies Involved in Therapeutics Development 35

Glaucoma-Drug Profiles 64

Glaucoma-Dormant Projects 252

Glaucoma-Discontinued Products 257

Glaucoma-Product Development Milestones 259

Appendix 267

List of Figures

Number of Products under Development for Glaucoma, H1 2017 20

Number of Products under Development by Companies, H1 2017 21

Number of Products under Development by Universities/Institutes, H1 2017 27

Number of Products by Top 10 Targets, H1 2017 35

Number of Products by Stage and Top 10 Targets, H1 2017 35

Number of Products by Top 10 Mechanism of Actions, H1 2017 39

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017 39

Number of Products by Top 10 Routes of Administration, H1 2017 43

Number of Products by Stage and Top 10 Routes of Administration, H1 2017 43

Number of Products by Top 10 Molecule Types, H1 2017 45

Number of Products by Stage and Top 10 Molecule Types, H1 2017 45

List of Tables

Number of Products under Development for Glaucoma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Glaucoma-Pipeline by AC Immune SA, H1 2017

Glaucoma-Pipeline by Advanced Refractive Technologies Inc, H1 2017

Glaucoma-Pipeline by Aerie Pharmaceuticals Inc, H1 2017

Glaucoma-Pipeline by Allergan Plc, H1 2017

Glaucoma-Pipeline by Altacor Ltd, H1 2017

Glaucoma-Pipeline by Amarantus Bioscience Holdings Inc, H1 2017

Glaucoma-Pipeline by Amgen Inc, H1 2017

Glaucoma-Pipeline by Annexon Inc, H1 2017

Glaucoma-Pipeline by Astellas Pharma Inc, H1 2017

Glaucoma-Pipeline by Bausch & Lomb Inc, H1 2017

Glaucoma-Pipeline by BioAxone BioSciences Inc, H1 2017

Glaucoma-Pipeline by Bionure Farma SL, H1 2017

Glaucoma-Pipeline by Can-Fite BioPharma Ltd, H1 2017

Glaucoma-Pipeline by Clearside BioMedical Inc, H1 2017

Glaucoma-Pipeline by D. Western Therapeutics Institute Inc, H1 2017

Glaucoma-Pipeline by Dompe Farmaceutici SpA, H1 2017

Glaucoma-Pipeline by Elsalys Biotech SAS, H1 2017

Glaucoma-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Glaucoma-Pipeline by Gene Signal International SA, H1 2017

Glaucoma-Pipeline by Gilead Sciences Inc, H1 2017

Glaucoma-Pipeline by Glaukos Corp, H1 2017

Glaucoma-Pipeline by Graybug Vision Inc, H1 2017

Glaucoma-Pipeline by Han Wha Pharma Co Ltd, H1 2017

Glaucoma-Pipeline by Handok Inc, H1 2017

Glaucoma-Pipeline by Icon Bioscience Inc, H1 2017

Glaucoma-Pipeline by ID Pharma Co Ltd, H1 2017

Glaucoma-Pipeline by InMed Pharmaceuticals Inc, H1 2017

Glaucoma-Pipeline by Inotek Pharmaceuticals Corp, H1 2017

Glaucoma-Pipeline by Ironwood Pharmaceuticals Inc, H1 2017

Glaucoma-Pipeline by Isarna Therapeutics GmbH, H1 2017

Glaucoma-Pipeline by Kukje Pharmaceutical Industry Co Ltd, H1 2017

Glaucoma-Pipeline by Laboratoires Thea SA, H1 2017

Glaucoma-Pipeline by Laboratorios SALVAT SA, H1 2017

Glaucoma-Pipeline by Laboratorios Sophia SA de CV, H1 2017

Glaucoma-Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017

Glaucoma-Pipeline by Lexicon Pharmaceuticals Inc, H1 2017

Glaucoma-Pipeline by Merck & Co Inc, H1 2017

Glaucoma-Pipeline by Mimetogen Pharmaceuticals Inc, H1 2017

Glaucoma-Pipeline by Nemus Bioscience Inc, H1 2017

Glaucoma-Pipeline by Neurim Pharmaceuticals Ltd, H1 2017

Glaucoma-Pipeline by NicOx SA, H1 2017

Glaucoma-Pipeline by NoNO Inc, H1 2017

Glaucoma-Pipeline by Novaliq GmbH, H1 2017

Glaucoma-Pipeline by Ocular Therapeutix Inc, H1 2017

Glaucoma-Pipeline by Oculis ehf, H1 2017

Glaucoma-Pipeline by Ohr Pharmaceutical Inc, H1 2017

Glaucoma-Pipeline by Profarma, H1 2017

Glaucoma-Pipeline by Q BioMed Inc, H1 2017

Glaucoma-Pipeline by Quark Pharmaceuticals Inc, H1 2017

Glaucoma-Pipeline by Regeneron Pharmaceuticals Inc, H1 2017

Glaucoma-Pipeline by Santen Pharmaceutical Co Ltd, H1 2017

Glaucoma-Pipeline by Senju Pharmaceutical Co Ltd, H1 2017

Glaucoma-Pipeline by Shire Plc, H1 2017

Glaucoma-Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017

Glaucoma-Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017

Glaucoma-Pipeline by Sun Pharmaceutical Industries Ltd, H1 2017

Glaucoma-Pipeline by Sylentis SAU, H1 2017

Glaucoma-Dormant Projects, H1 2017

Glaucoma-Dormant Projects, H1 2017 (Contd..1), H1 2017

Glaucoma-Dormant Projects, H1 2017 (Contd..2), H1 2017

Glaucoma-Dormant Projects, H1 2017 (Contd..3), H1 2017

Glaucoma-Dormant Projects, H1 2017 (Contd..4), H1 2017

Glaucoma-Discontinued Products, H1 2017

Glaucoma-Discontinued Products, H1 2017 (Contd..1), H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AC Immune SA, Advanced Refractive Technologies Inc, Aerie Pharmaceuticals Inc, Allergan Plc, Altacor Ltd, Amarantus Bioscience Holdings Inc, Amgen Inc, Annexon Inc, Astellas Pharma Inc, Bausch & Lomb Inc, BioAxone BioSciences Inc, Bionure Farma SL, Can-Fite BioPharma Ltd, Clearside BioMedical Inc, D. Western Therapeutics Institute Inc, Dompe Farmaceutici SpA, Elsalys Biotech SAS, F. Hoffmann-La Roche Ltd, Gene Signal International SA, Gilead Sciences Inc, Glaukos Corp, Graybug Vision Inc, Han Wha Pharma Co Ltd, Handok Inc, Icon Bioscience Inc, ID Pharma Co Ltd, InMed Pharmaceuticals Inc, Inotek Pharmaceuticals Corp, Ironwood Pharmaceuticals Inc, Isarna Therapeutics GmbH, Kukje Pharmaceutical Industry Co Ltd, Laboratoires Thea SA, Laboratorios SALVAT SA, Laboratorios Sophia SA de CV, Lee's Pharmaceutical Holdings Ltd, Lexicon Pharmaceuticals Inc, Merck & Co Inc, Mimetogen Pharmaceuticals Inc, Nemus Bioscience Inc, Neurim Pharmaceuticals Ltd, NicOx SA, NoNO Inc, Novaliq GmbH, Ocular Therapeutix Inc, Oculis ehf, Ohr Pharmaceutical Inc, Profarma, Q BioMed Inc, Quark Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc, Santen Pharmaceutical Co Ltd, Senju Pharmaceutical Co Ltd, Shire Plc, SK Biopharmaceuticals Co Ltd, Sun Pharma Advanced Research Company Ltd, Sun Pharmaceutical Industries Ltd, Sylentis SAU

select a license

Single User License
USD 2000 INR 129140
Site License
USD 4000 INR 258280
Corporate User License
USD 6000 INR 387420

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com